HUTCHMED licenses cancer drug for $110 million
HUTCHMED (NASDAQ:HCM) signed an exclusive development and license agreement with a GSK subsidiary for HMPL-A830, a KRAS-EGFR Antibody-Targeted Therapy Conjugate, covering worldwide rights outside Mainland China, Hong Kong, Macau, and Taiwan.










